PF-114
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background: PF-114 mesylate is a novel third generation oral tyrosine kinase inhibitor (TKI) that blocks native and mutated Bcr…
Background & Aims. The chimeric tyrosine kinase Bcr-Abl triggers malignant transformation of myeloid cells via phosphorylation of…
ABSTRACT This review focuses on association between the selectiv-ity of Bcr-Abl kinase inhibitors and the spectrum of their…
Background Targeting BCR/ABL by ABL-directed kinase inhibitors (AKIs) induces long lasting remissions in patients with chronic…